The additional value of routine electrocardiograms in cardiovascular risk management of older people

Scandinavian Journal of Primary Health Care

Volumn 26, Issue 3, 2008, Pages 147-153

  De Ruijter, Wouter ^a   Assendelft, Willem J J ^a   MacFarlane, Peter W ^b   Westendorp, Rudi G J ^a   Gussekloo, Jacobijn ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Aged; Aged 80 and over; Cardiovascular diseases; Electrocardiography; Family practice; Medical records; Risk management

Indexed keywords

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ECG ABNORMALITY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORBIDITY; MORTALITY; OBSERVATIONAL STUDY; PATIENT CARE; POPULATION; PROSPECTIVE STUDY; RISK MANAGEMENT;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; MALE; MEDICAL RECORDS; MYOCARDIAL INFARCTION; NETHERLANDS; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS;

EID: 50849129577     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430802095812     Document Type: Article

References (30)

1. Strandberg TE, Pitkala KH, Berglind S, Nieminen MS, Tilvis RS. Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: The Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: A randomized, controlled trial. Am Heart J 2006;152:585-92.
2. Bulpitt CJ. Secondary prevention of coronary heart disease in the elderly. Heart 2005;91:396-400.
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
4. Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-30.
5. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001;134:931-40.
6. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: Cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821.
7. Gotto AM, Jr. Statin therapy and the elderly: SAGE Advice? Circulation 2007;115:681-3.
8. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-97.
9. Fox KM, Bertrand M, Ferrari R, Remme WJ, Simoons ML, Remme WJ, et al. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8.
10. Williams MA, Fleg JL, Ades PA, Chaitman BR, Miller NH, Mohiuddin SM, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients > = 75 years of age): An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735-43.
11. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
12. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-72.
13. Clinical Guideline A. Prophylaxis for patients who have experienced a myocardial infarction. London: National Institute for Clinical Excellence; 2006.
14. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-923.
15. De Ruijter W, Westendorp RGJ, Macfarlane PW, Jukema JW, Assendelft WJJ, Gussekloo J. The routine electrocardiogram for cardiovascular risk stratification in old age: The Leiden 85-Plus Study. J Am Geriatr Soc 2007;55:872-7.
16. Sheifer SE, Gersh BJ, Yanez ND, III, Ades PA, Burke GL, Manolio TA. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000;35:119-26.
17. Nadelmann J, Frishman WH, Ooi WL, Tepper D, Greenberg S, Guzik H, et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990;66:533-7.
18. Macfarlane PW, Latif S. Automated serial ECG comparison based on the Minnesota code. J Electrocardiol 1996;29(Suppl):29-34.
19. Prineas RJ, Crow RS, Blackburn H. The Minnesota code manual of electrocardiographic findings: Standards and procedures for measurement and classification. Boston, MA: Wright; 1982.
20. World Health Organization. International Classification of Diseases and Related Disorders. Geneva: World Health Organization; 2006.
21. Mitka M. Electronic health records, after-hours care lag in US primary care practices. JAMA 2006;296:2913-4.
22. Sheifer SE, Manolio TA, Gersh BJ. Unrecognized myocardial infarction. Ann Intern Med 2001;135:801-11.
23. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death. Circulation 1998;98:946-52 .
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.
25. O'Donnell CJ, Glynn RJ, Field TS, Averback R, Satterfield S, Friesenger GC, et al. Misclassification and under-reporting of acute myocardial infarction by elderly persons: Implications for community-based observational studies and clinical trials. J Clin Epidemiol 1999;52:745-51.
26. Kors JA, van Herpen G, Wu J, Zhang Z, Prineas RJ, van Bemmel JH. Validation of a new computer program for Minnesota coding. J Electrocardiol 1996;29 (Suppl):83-8.
27. Tuinstra CL, Rautaharju PM, Prineas RJ, Duisterhout JS. The performance of three visual coding procedures and three computer programs in classification of electrocardiograms according to the Minnesota Code. J Electrocardiol 1982;15:345-50.
28. Ramsay SE, Whincup PH, Lawlor DA, Papacosta O, Lennon LT, Thomas MC, et al. Secondary prevention of coronary heart disease in older patients after the national service framework: Population based study. BMJ 2006;332:144-5.
29. Sudlow M, Rodgers H, Kenny RA, Thomson R. Population based study of use of anticoagulants among patients with atrial fibrillation in the community. BMJ 1997;314:1529-30.
30. Tran CTT, Laupacis A, Mamdani MM, Tu JV. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J 2004;148:834-41.